Combined genome-wide CRISPR knockout screening with base editor tiling screens at amino acid resolution reveal molecular rules governing HUWE1 phospho-degron recognition and identify a regulatory gate controlling substrate engagement and illustrate a generalizable strategy for resolving degradation mechanisms of undruggable transcription factors in their endogenous cellular context.
Abstract
Lineage-defining transcription factors are key oncogenic drivers but remain difficult to target pharmacologically due to the absence of ligandable pockets. The molecular rules governing substrate recognition by large HECT ubiquitin ligases also remain incompletely understood, limiting efforts to exploit these enzymes for targeted protein degradation. Here we combine genome-wide CRISPR knockout screening with base editor tiling screens at amino acid resolution, both coupled to an endogenous knock-in reporter of the SCLC lineage oncogenic transcription factor ASCL1, to systematically interrogate the mechanisms governing its degradation. These complementary screens unbiasedly identify the HECT ubiquitin ligase HUWE1 as the dominant regulator of ASCL1 stability in small cell lung cancer (SCLC) and resolve a conserved C-terminal phospho-degron centered on Ser207 and terminal Trp/Phe residues that are required for HUWE1 docking and ubiquitin-mediated degradation. Unexpectedly, base editor screening further uncovers a previously unrecognized regulatory module within HUWE1: a short negatively charged helix that functions as an autoinhibitory gate controlling access of phospho-degron substrates to HUWE1. Charge-flipping mutations within this regulatory helix relieve autoinhibition and accelerate degradation of multiple HUWE1 phospho-degron substrates, including ASCL1 and the canonical HUWE1 substrate DDIT4. Stabilization of ASCL1 through degron disruption paradoxically impairs SCLC proliferation, revealing that dynamic proteasome-coupled turnover is required for transcription factor function. Together, these findings reveal molecular rules governing HUWE1 phospho-degron recognition and identify a regulatory gate controlling substrate engagement. They also illustrate a generalizable strategy for resolving degradation mechanisms of undruggable transcription factors in their endogenous cellular context.
Experimental strategies to identify UID degrons that mediate degradation by the catalytic 20S proteasome particle are described and an integrated workflow-spanning degron mapping to functional validation-provides a generalizable framework for uncovering ubiquitin-independent degrons.
Y. Shaul· Methods in molecular biology· 0 citations
A novel interconnected regulatory cascade triggered by nuclear translocation of GDOWN1 is uncovered: it remodels Pol II phosphorylation landscape and induces global transcriptional repression, which further drives cytoplasmic kinase-phosphatase coordination to activate master cell cycle suppressors and ultimately arres...
Zhanwu Zhu, Jin-Jing Hu, Wen-Yuan Zhu et al.· Cell Death and Differentiati...· 0 citations
The HUWE1-HAPSTR1-USP7 complex is established as a key ubiquitin code modifier, providing a molecular rationale for HUWE1 dysregulation in neurodevelopmental disorders and cancer.
S. Yatskevich, Jugal Mohapatra, R. Mroue et al.· Molecules and Cells· 0 citations
Findings reveal the unique ability of uAbs to selectively deplete abnormal proteins in vitro and in vivo and open the door to peptide-programmable biologic modulators of other disease-causing proteins.
Tianzheng Ye, A. Alamgir, C. Robertus et al.· Science Advances· 0 citations
This review summarizes classic and recent findings on structural biology, PTM networks, mutation landscapes, oncogenic mechanisms, and therapeutic frontiers, highlighting TWIST1 as a target for precision oncology and therapy.
Bruno Ricardo Barreto Pires, G. Ferreira, E. Abdelhay· Biochimica et biophysica act...· 0 citations
The FEN1/EIF4A3/MUC1-C axis is established as a novel mechanism driving LUAD progression by concurrently regulating intrinsic malignancy and extrinsic immune evasion, presenting FEN1 targeting as a promising dual-hit therapeutic strategy.
Min Wu, Ben-Meng Wu, Xue-Bing Yan et al.· Cell Death and Disease· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.